EARLY ACS TIMI 39

OBJECTIVE: To assess the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST segment elevation acute coronary syndrome.

View/Download
_______________________________________________________________________________

1. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (Early-ACS) trial. A randomized, placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome – Study design and rationale. Giugliano RP, Newby KL, Harrington RA, Gibson CM, van de Werf F, Armstrong PW, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E. Am Heart J 2005;149:994-1002.
   | Abstract | Request Reprints |